{
  "Variants Include": [
    {
      "Gene": "SNCA",
      "variants": [
        {
          "HGVS": "NM_001143661.2:c.158C>T",
          "cDNA Change": {
            "transcript": "NM_001143661.2",
            "ref": "C",
            "alt": "T",
            "position": "158"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "V",
            "position": "53"
          },
          "Description in input context": "A53T"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0005180"
  },
  "Experiment Method": [
    {
      "Assay Method": "Immunohistochemistry",
      "Material used": {
        "Material Source": "Patients Derived Material",
        "Material Name": "Postmortem brain tissue",
        "Description": "Postmortem brain tissue from a patient in the Contursi kindred carrying the A53T a-syn gene mutation."
      },
      "Readout type": "Qualitative",
      "Readout description": [
        {
          "Variant": "NM_001143661.2:c.158C>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "gain-of-function",
          "Result Description": "Insoluble filamentous a-syn lesions were detected in almost all brain regions examined. Significant accumulations of filamentous insoluble tau protein also were detected in some brain regions."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "No",
        "Description": "N.D."
      },
      "Technical replicates": {
        "Technical replicates": "No",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Immunostaining of brain sections for a-syn was optimized by pretreating sections in 88% formic acid (FA) for 30 min."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Absence of insoluble a-syn and tau in brain regions.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Detection of insoluble filamentous a-syn and tau in brain regions.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "Western Blot",
      "Material used": {
        "Material Source": "Patients Derived Material",
        "Material Name": "Frozen brain tissue",
        "Description": "Frozen brain tissue from cingulate cortex, midfrontal cortex, cerebellum and hippocampus, and 10 different subcortical areas."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_001143661.2:c.158C>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "gain-of-function",
          "Result Description": "A significant portion of a-syn in cingulate cortex from case IX-51 is extractable only with SDS, and a larger pool is solubilized only with FA, indicating insoluble a-syn.  Western blots with nSyn14 antibody confirmed the presence of nitrated a-syn in FA extracts of hippocampus and cingulate cortex."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "No",
        "Description": "N.D."
      },
      "Technical replicates": {
        "Technical replicates": "No",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "N.D."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Levels of a-syn and tau comparable to healthy controls.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Increased levels of insoluble and nitrated a-syn and tau compared to healthy controls.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "Electron Microscopy",
      "Material used": {
        "Material Source": "Patients Derived Material",
        "Material Name": "Brain sections and sarkosyl-insoluble material",
        "Description": "Selected brain sections and sarkosyl-insoluble material from hippocampus and dorsal pons."
      },
      "Readout type": "Qualitative",
      "Readout description": [
        {
          "Variant": "NM_001143661.2:c.158C>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "gain-of-function",
          "Result Description": "Immuno-EM studies of inclusions labeled with antibodies to a-syn revealed characteristic spheroids that frequently showed a filamentous ultrastructure. Inclusions containing tau fibrils were also detected in situ. Isolated sarkosyl-insoluble material from hippocampus and dorsal pons contains a-syn and tau filaments."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "No",
        "Description": "N.D."
      },
      "Technical replicates": {
        "Technical replicates": "No",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Sections were labeled with antibody Syn 303 or PHF-1 and sequentially incubated with a biotinylated goat anti-mouse antibody and HRP-conjugated streptavidin."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Absence of filamentous structures and inclusions.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Presence of filamentous structures and inclusions containing a-syn and tau.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "In vitro fibrillization assays",
      "Material used": {
        "Material Source": "Recombinant protein",
        "Material Name": "Recombinant tau T40, wild-type a-syn, and A53T mutant a-syn",
        "Description": "Polymerization of bacterial recombinant tau T40 with recombinant wild-type (WT) and A53T mutant a-syn."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_001143661.2:c.158C>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "gain-of-function",
          "Result Description": "Fibril assembly was much faster for A53T compared to WT a-syn, and coassembly experiments showed that the rates of assembly of a-syn and tau were accelerated when A53T instead of WT a-syn was used."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "N = 4 samples"
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Tau T40 was incubated at a concentration of 1 mg/ml for all experiments."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Fibrillization rates comparable to wild-type a-syn",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Accelerated fibrillization rates compared to wild-type a-syn",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}